European Union´s Horizon 2020 – Lipum2019-07-05T11:00:21+00:00

OFFICAL PROJECT SITE 

Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

2103, 2019

Lipum attracts interest from life science leaders

March 21st, 2019|

Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and venture capital segments. These events take place March 25-27 and provides an opportunity to meet, please contact us and learn [...]

1903, 2019

Lipum and Abzena sign integrated CMC agreement

March 19th, 2019|

Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory [...]

403, 2019

Lipum to NASDAQ

March 4th, 2019|

On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for EIC pilot- funded companies with the opportunity to pitch their business to top European investors and connect with Nasdaq representatives [...]

1602, 2019

New share issue round about to close on Sunday 17 February

February 16th, 2019|

Tomorrow, Lipum will close a share issue raising SEK 25 million in addition to support from Horizon 2020 of SEK 23 million grant. The capital will finance the preclinical work and the development of a production method up to the start of toxicology studies next year. See the full [...]

Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€

Start:
2018-11-01

End:
2020-07-31